We are a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs.
At SteadyMed we are executing a highly focused strategy that is designed to create value for our shareholders in the short term by leveraging the technology and patient benefits of our PatchPump delivery system.
1) Specialty pharmaceutical product development is our primary focus
Our primary focus is our investigational drug product candidate, Trevyent®, which is designed to address a number of unmet needs in the treatment of pulmonary arterial hypertension (PAH). Trevyent combines SteadyMed’s preservative-free, treprostinil formulation with its proprietary PatchPump®. We are expanding our therapeutic portfolio by also developing 2 products to support the management of pain in the ambulatory setting; At Home Patient Analgesia (AHPA).
2) Our secondary focus is licensing
A) Our primary partnering objective is to provide innovator or biosimilar companies an opportunity to differentiate, defend and grow their market positions.
B) PatchPump is an advanced prefilled, programmable, electronically controlled and disposable system in development. In addition, PatchPump has the ability to deliver viscous drugs in high volumes. As such, PatchPump offers a simple and elegant solution to BioPharmaceutical companies looking for a platform technology to deliver a range of drug products with volumes greater than 2mL.
SteadyMed embraces an individual, customized approach to our partnering efforts. To that end, we offer a number of collaboration options to best meet your needs; from early stage Feasibility Assessment, through full License and Supply Agreements. To learn more about partnering with SteadyMed, please contact us.